The testing strategy for detection of biologically relevant infection of human papillomavirus in head and neck tumors for routine pathological analysis
Authors:
Jana Kašpírková 1; Ondrej Ondič 1
; Kateřina Černá 1; Alena Skálová 1,2
Authors place of work:
Bioptická laboratoř s. r. o., Plzeň
1; Šiklův ústav patologie, Univerzita Karlova v Praze, Lékařská fakulta v Plzni, Plzeň
2
Published in the journal:
Čes.-slov. Patol., 49, 2013, No. 1, p. 29-34
Category:
Original Article
Summary
There is a subgroup among head and neck squamous cell carcinomas, which is etiologically linked to the infection of high-risk human papillomavirus (HPV). In recent studies, HPV related squamous cell carcinomas have been placed in a separate group because of their different epidemiology, distinctive histopathological characteristics, therapeutic response and clinical outcome. The reported prevalence of high-risk HPV in head and neck tumors varies in different studies. This fact occurs mainly due to the absence of a widely accepted consensus for HPV detection in head and neck malignancies.
We present a methodological algorithm for detection of biologically relevant HPV infection:
a combination of an immunohistochemical staining of the p16 protein – a surrogate marker for a transforming HPV infection, and a molecular genetic identification of HPV DNA by three different polymerase chain reactions (PCR). The study group consisted of 41 patients with a tumor in head and neck region. A verification of detection of biologically relevant HPV infection has been performed in 10 available samples using an alternative approach, which comprised the detection of RNA transcript of HPV by reverse transcription followed by PCR (RT-PCR), and further in situ hybridization (ISH) with a commercial high-risk HPV probe.
We have found a high correlation between HPV DNA detection using triple-PCR approach and strong diffuse positivity of the p16 protein (correlation coefficient 0.94) and have confirmed the validity of this algorithm. In 94 % of HPV related squamous cell carcinomas HPV type 16 was detected. In one case HPV type 33 was identified. That is in agreement with earlier published data. A more appropriate alternative method for the detection of biologically relevant- transforming HPV infection seems to be RT-PCR, which proved 100 % agreement with the original methodological approach of p16 determination and PCR status.
Interpretation of the ISH has been complicated by frequent nonspecific staining of the sample and its routine usage in the diagnostic algorithm of our laboratory is currently not feasible.
Keywords:
HPV – squamous cell carcinoma – head and neck tumors – p16
Zdroje
1. zur Hausen H. The search for infectious causes of human cancers: where and why. Virology 2009; 392(1): 1–10.
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2(5): 342–350.
3. Katzenellenbogen RA, Galloway DA. Human papillomavirus-associated cancers. In:Viral Oncology-Basic Science and Clinical Applications, 1st ed, New Yersey: Wiley- Blackwell, 2009: 1–23.
4. MuĖoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 31, Suppl 3: S3/1–10.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12–19.
6. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14(2): 467–475.
7. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121 (11): 2465–2472.
8. Syrjänen SM, Syrjänen KJ, Happonen RP. Human papillomavirus (HPV) DNA sequences in oral precancerous lesions and squamous cell carcinoma demonstrated by in situ hybridization. J Oral Pathol 1988; 17(6): 273–278.
9. Ostwald C, Müller P, Barten M, et al. Human papillomavirus DNA in oral squamous cell carcinomas and normal mucosa. J Oral Pathol Med 1994; 23(5): 220–225.
10. Zeuss MS, Miller CS, White DK. In situ hybridization analysis of human papillomavirus DNA in oral mucosal lesions. Oral Surg Oral Med Oral Pathol 1991; 71(6): 714–720.
11. Koppikar P, de Villiers EM, Mulherkar R. Identification of human papillomaviruses in tumors of the oral cavity in an Indian community. Int J Cancer 2005; 113(6): 946–950.
12. Klozar J, Tachezy R, Rotnáglová E, Koslabová E, Saláková M, Hamšíková E. Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects. Wien Med Wochenschr 2010; 160(11-12): 305–309.
13. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125(2): 362–366.
14. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24(5): 736–747.
15. Syrjänen KJ, Pyrhönen S, Syrjänen SM, Lamberg MA. Immunohistochemical demonstration of human papilloma virus (HPV) antigens in oral squamous cell lesions. Br J Oral Surg 1983; 21(2): 147–153.
16. Lambert R, Sauvaget C, de Camargo Cancela M, Sankaranarayanan R. Epidemiology of cancer from the oral cavity and oropharynx. Eur J Gastroenterol Hepatol 2011; 23(8): 633–641.
17. Snow AN, Laudadio J. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol 2010; 17(6): 394 –403.
18. Westra WH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 2009; 3(1): 78–81.
19. Ang KK, Harris J, Wheeler R. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 36(1): 24–35.
20. Remmerbach TW, Brinckmann UG, Hemprich A, Chekol M, Kühndel K, Liebert UG. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J Clin Virol 2004; 30(4): 302–308.
21. Morshed K, Polz-Dacewicz M, Szymański M, Polz D. Short-fragment PCR assay for highly sensitive broad-spectrum detection of human papillomaviruses in laryngeal squamous cell carcinoma and normal mucosa: clinico-pathological evaluation. Eur Arch Otorhinolaryngol 2008; 265, (Suppl.1): 89–96.
22. Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med 2005; 43(11): 1171–1177.
23. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996; 34(9): 95–100.
24. Poljak M, Ostrbenk A, Seme K, et al. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011; 49(5): 1721–1729.
25. Romagosa C, Simonetti S, López-Vicente L, et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011; 30(18): 2087–2097.
26. Mulvany NJ, Allen DG, Wilson SM. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology 2008; 40(4): 335 –344.
27. Campisi G, Giovannelli L. Controversies surrounding human papilloma virus infection, head & neck vs oral cancer, implications for prophylaxis and treatment. Head Neck Oncol 2009; 30: 1:8.
28. D’Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356(19): 1944–1956.
29. van Dongen JJ, Langera AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17(12): 2257–2317.
30. Gaffney R, Chakerian A, O’Connell JX, et al.: Novel fluorescent ligase detection reaction and flow cytometric analysis of SYT-SSX fusions in synovial sarcoma. J Mol Diagn 2003; 5(2): 127 –135.
31. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997; 35(3): 791–795.
32. Tieben LM, ter Schegget J, Minnaar RP, et al. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993; 42(2-3): 265–279.
33. Skálová A, Kašpírková - Němcová J, Vaněček T. Role of Human Papillomaviruses (HPV) in salivary gland tumors. Cesk Patol 2013 - v tisku.
34. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11(8): 781–789.
35. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 2009; 140(2): 228 –234.
36. Pannone G, Rodolico V, Santoro A, et al. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer 2012; 29: 7:4.
37. Wadsworth B, Bumpous JM, Martin AW, Nowacki MR, Jenson AB, Farghaly H. Expression of p16 in Sinonasal Undifferentiated Carcinoma (SNUC) Without Associated Human Papillomavirus (HPV). Head Neck Pathol 2011; 5(4): 349–354.
38. Lewis JS Jr, Thorstad WL, Chernock RD, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010; 34(8): 1088–1096.
39. Cantley RL, Gabrielli E, Montebelli F, Cimbaluk D, Gattuso P, Petruzzelli G. Ancillary studies in determining human papillomavirus status of squamous cell carcinoma of the oropharynx: a review. Patholog Res Int 2011; 138469, Epub.
40. Termine N, Panzarella V, Falaschini S. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 2008; 19(10): 1681–1690.
41. Herrero R, Castellsagué X, Pawlita M, et al. IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95(23): 1772–1783.
42. Rotnáglová E, Tachezy R, Saláková M, et al. HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers. Int J Cancer 2011; 129(1): 101–110.
43. Schlecht NF, Brandwein-Gensler M, Nuovo GJ, et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol 2011; 24(10): 1295 –1305.
44. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10(5): R75, Epub.
45. Bastide K, Guilly MN, Bernaudin JF, et al. Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors. Lung Cancer 2009; 63(3): 348–353.
Štítky
Anatomical pathology Forensic medical examiner ToxicologyČlánok vyšiel v časopise
Czecho-Slovak Pathology
2013 Číslo 1
Najčítanejšie v tomto čísle
- Czech eponyms in pathology
-
Gastric dysplasias.
A clinicopathological study of 35 cases - Autophagic vacuolar myopathies: what we have learned from the differential diagnosis of vacuoles in muscle biopsy
-
Nanopathology as a new scientific discipline
Minireview